GB1598053A
(en)
*
|
1978-01-31 |
1981-09-16 |
Fisons Ltd |
Pocket inhaler
|
US4262666A
(en)
*
|
1979-10-24 |
1981-04-21 |
Nelson Byron G |
Inhalator-breathing apparatus
|
IE50472B1
(en)
*
|
1979-10-30 |
1986-04-30 |
Riker Laboratories Inc |
Breath actuated devices for administering powdered medicaments
|
US4261354A
(en)
*
|
1979-11-26 |
1981-04-14 |
Nelson Byron G |
Inhalator-breathing apparatus
|
US4570630A
(en)
*
|
1983-08-03 |
1986-02-18 |
Miles Laboratories, Inc. |
Medicament inhalation device
|
US4655231A
(en)
*
|
1984-01-09 |
1987-04-07 |
Advanced Tobacco Products, Inc. |
Snuff and preparation thereof
|
JPS63143081A
(ja)
*
|
1986-12-05 |
1988-06-15 |
メクト株式会社 |
吸入器
|
US5161524A
(en)
*
|
1991-08-02 |
1992-11-10 |
Glaxo Inc. |
Dosage inhalator with air flow velocity regulating means
|
US5469843A
(en)
*
|
1991-11-12 |
1995-11-28 |
Minnesota Mining And Manufacturing Company |
Inhalation device
|
US5305658A
(en)
*
|
1992-07-01 |
1994-04-26 |
Sterling Winthrop Inc. |
Capsule transfer device
|
US6582728B1
(en)
*
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
KR960701672A
(ko)
*
|
1993-03-03 |
1996-03-28 |
윌리엄 피. 알트만 |
건조 분말 흡입기의 약제 캐리어(dry powder inhalator medicament carrier)
|
WO1994023772A2
(en)
*
|
1993-04-06 |
1994-10-27 |
Minnesota Mining And Manufacturing Company |
Deagglomerators for dry powder inhalers
|
US5388572A
(en)
*
|
1993-10-26 |
1995-02-14 |
Tenax Corporation (A Connecticut Corp.) |
Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
|
US5388573A
(en)
*
|
1993-12-02 |
1995-02-14 |
Tenax Corporation |
Dry powder inhalator medicament carrier
|
PT101450B
(pt)
*
|
1994-02-02 |
1999-11-30 |
Hovione Produtos Farmaceuticos |
Novo dispositivo para inalacao
|
CN1073119C
(zh)
*
|
1994-05-18 |
2001-10-17 |
吸入治疗系统公司 |
干扰素干粉配方的方法及组合物
|
US6290991B1
(en)
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
SE9502800D0
(sv)
*
|
1995-08-10 |
1995-08-10 |
Astra Ab |
Disposable inhaler
|
US5669378A
(en)
*
|
1995-12-21 |
1997-09-23 |
Pera; Ivo |
Inhaling device
|
US20030203036A1
(en)
*
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
US20030035778A1
(en)
*
|
1997-07-14 |
2003-02-20 |
Robert Platz |
Methods and compositions for the dry powder formulation of interferon
|
DE19835346A1
(de)
*
|
1998-08-05 |
2000-02-10 |
Boehringer Ingelheim Pharma |
Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
|
AU2001283546A1
(en)
|
2000-08-14 |
2002-02-25 |
Advanced Inhalation Research, Inc. |
Inhalation device and method
|
US6766799B2
(en)
*
|
2001-04-16 |
2004-07-27 |
Advanced Inhalation Research, Inc. |
Inhalation device
|
WO2003078448A1
(en)
|
2002-03-13 |
2003-09-25 |
Signum Biosciences, Inc. |
Modulation of protein methylation and phosphoprotein phosphate
|
US20060045849A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Farhan Taghizadeh |
Method of customizing the fragrance of nasal medications
|
DE102005001332A1
(de)
*
|
2005-01-11 |
2006-07-20 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Zweiteilige Kapsel mit Vorverschluss zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
|
US7923041B2
(en)
|
2005-02-03 |
2011-04-12 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
US8221804B2
(en)
*
|
2005-02-03 |
2012-07-17 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
US8653028B2
(en)
*
|
2005-04-29 |
2014-02-18 |
Rui Rong Yuan |
Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
|
US9585932B2
(en)
|
2005-04-29 |
2017-03-07 |
Peter C. Dowling |
Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
|
US9345745B2
(en)
|
2005-04-29 |
2016-05-24 |
Bo Wang |
Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
|
WO2007024876A2
(en)
*
|
2005-08-24 |
2007-03-01 |
The Board Of Trustees Of Leland Stanford Junior University |
Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis
|
US20090192227A1
(en)
*
|
2005-08-24 |
2009-07-30 |
Rabindra Tirouvanziam |
N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
|
US8227408B2
(en)
*
|
2005-09-07 |
2012-07-24 |
Neurotez, Inc. |
Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
|
US9107824B2
(en)
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
EP2606903B1
(en)
|
2007-01-10 |
2016-09-14 |
Purdue Research Foundation |
Polypeptide inhibitors of HSP27 kinase and uses therefor
|
WO2008156586A2
(en)
*
|
2007-06-12 |
2008-12-24 |
Alkermes, Inc. |
Inhalation device for powdered substances
|
WO2009021137A2
(en)
*
|
2007-08-07 |
2009-02-12 |
Purdue Research Foundation |
Kinase inhibitors and uses thereof
|
JP5622720B2
(ja)
*
|
2008-05-21 |
2014-11-12 |
ニューロテスインコーポレイテッド |
神経原繊維変化に関連する進行性認知障害の治療方法
|
AU2009322865B2
(en)
*
|
2008-10-20 |
2013-07-18 |
Moerae Matrix, Inc. |
Polypeptide for treating or preventing adhesions
|
AU2009313562B2
(en)
*
|
2008-11-04 |
2012-11-15 |
Neurotez, Inc. |
Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
|
AU2009324661A1
(en)
*
|
2008-12-10 |
2011-07-07 |
Purdue Research Foundation |
Cell-permeant peptide-based inhibitor of kinases
|
EP2456772A4
(en)
|
2009-07-24 |
2013-02-27 |
Amazentis Sa |
COMPOUNDS, COMPOSITIONS AND METHODS FOR PROTECTING BRAIN HEALTH IN NEURODEGENERATIVE DISORDERS
|
US9890195B2
(en)
|
2009-07-27 |
2018-02-13 |
Purdue Research Foundation |
MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
|
US9890200B2
(en)
|
2011-04-12 |
2018-02-13 |
Moerae Matrix, Inc. |
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
|
WO2012142320A2
(en)
|
2011-04-12 |
2012-10-18 |
Moerae Matrix Inc |
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
|
CN103619340B
(zh)
|
2011-04-25 |
2016-08-17 |
康奈尔大学 |
尿苷和脱氧尿苷在治疗叶酸应答性病变中的用途
|
EP2589381B1
(en)
|
2011-11-04 |
2016-08-31 |
Rabindra Tirouvanziam |
Compositions for improving or preserving lung function in a patient with a pulmonary disorder
|
WO2013134636A1
(en)
|
2012-03-09 |
2013-09-12 |
Purdue Research Foundation |
Compositions and methods for delivery of kinase inhibiting peptides
|
DK2892524T3
(da)
|
2012-09-04 |
2021-01-25 |
Eleison Pharmaceuticals LLC |
Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin
|
ES2811090T3
(es)
|
2013-09-10 |
2021-03-10 |
Univ Texas |
Terapéuticos dirigidos a proteínas truncadas de poliposis adenomatosa coli (apc)
|
US10336788B2
(en)
|
2014-04-17 |
2019-07-02 |
Moerae Matrix, Inc. |
Inhibition of cardiac fibrosis in myocardial infarction
|
US10082496B2
(en)
|
2014-09-10 |
2018-09-25 |
Board Of Regents Of The University Of Texas System |
Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
|
CA2967621A1
(en)
|
2014-11-17 |
2016-05-26 |
Moerae Matrix, Inc. |
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
|
CA2970140A1
(en)
|
2014-12-10 |
2016-06-16 |
Hyperstem, SA |
Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors
|
WO2016112292A1
(en)
|
2015-01-08 |
2016-07-14 |
Moerae Matrix, Inc. |
Formulation of mk2 inhibitor peptides
|
CA2978941A1
(en)
|
2015-03-12 |
2016-09-15 |
Moerae Matrix, Inc. |
Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
|
CA2987071A1
(en)
|
2015-06-10 |
2016-12-15 |
Hackensack University Medical Center |
Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
|
CN107949279A
(zh)
|
2015-07-06 |
2018-04-20 |
得克萨斯系统大学评议会 |
可用作用于治疗人类癌症的抗癌剂的苯甲酰胺或苯扎明化合物
|
WO2017011215A1
(en)
|
2015-07-15 |
2017-01-19 |
The Board Of Regents Of The University Of Texas System |
Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
|
US11833118B2
(en)
|
2016-01-20 |
2023-12-05 |
Flurry Powders, Llc |
Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
|
AU2017210319A1
(en)
|
2016-01-20 |
2018-08-23 |
Flurry Powders, Llc |
Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
|